A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
The post Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval appeared first on MGH Center for Women’s Mental Health.